Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
classic Hodgkin lymphoma
diffuse large B-cell lymphoma
immune escape
immunodeficiency
programmed cell death 1 ligand 1
Journal
Journal of clinical and experimental hematopathology : JCEH
ISSN: 1880-9952
Titre abrégé: J Clin Exp Hematop
Pays: Japan
ID NLM: 101141257
Informations de publication
Date de publication:
22 Dec 2021
22 Dec 2021
Historique:
pubmed:
14
9
2021
medline:
14
1
2022
entrez:
13
9
2021
Statut:
ppublish
Résumé
The programmed cell death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumor cell escape from immune control and has been most extensively investigated for therapeutic purposes. However, PD-L1 immunohistochemistry is still not used widely for diagnosis. We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL. Of note, EBV+ CHL often poses a challenge for differential diagnosis from peripheral T-cell lymphoma with EBV+ non-malignant large B-cells; their distinction is based on the lack of PD-L1 expression on large B-cells in the latter. The nPD-L1 expression further provides a good diagnostic consensus for CHL with primary extranodal disease conceivably characterized by a combined pathogenesis of immune escape of tumor cells and immunodeficiency. Compared with CHL, the nPD-L1 expression rate is much lower in DLBCL, highlighting some specific subgroups of intravascular large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and EBV+ DLBCL. They consist of nPD-L1-positive and -negative subgroups, but their clinicopathological significance remains to be elucidated. Microenvironmental PD-L1 positivity on immune cells may be associated with a favorable prognosis in extranodal DLBCL. PD-L1 (by SP142) immunohistochemistry has helped us to understand the immune biology of lymphoid neoplasms possibly related by immune escape and/or immunodeficiency. However, knowledge of these issues remains limited and should be clarified for diagnostic consensus in the future.
Identifiants
pubmed: 34511582
doi: 10.3960/jslrt.21003
pmc: PMC8808108
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Ligands
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
182-191Références
Clin Cancer Res. 2012 Mar 15;18(6):1611-8
pubmed: 22271878
Pathol Int. 2019 Dec;69(12):697-705
pubmed: 31872533
Blood. 2015 Aug 13;126(7):863-72
pubmed: 25999451
Blood. 2021 Mar 18;137(11):1491-1502
pubmed: 33512416
Am J Surg Pathol. 2013 Jun;37(6):816-26
pubmed: 23598959
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Clin Cancer Res. 2007 Sep 1;13(17):5124-32
pubmed: 17785567
Cancer Sci. 2008 Jun;99(6):1085-91
pubmed: 18429953
Cancer Med. 2018 Dec;7(12):6051-6063
pubmed: 30449068
Hum Pathol. 2016 Aug;54:17-24
pubmed: 27045512
Br J Haematol. 2014 Feb;164(4):536-45
pubmed: 24245986
Ann Clin Lab Sci. 2016 Spring;46(2):219-21
pubmed: 27098632
Adv Hematol. 2011;2011:
pubmed: 20936156
Hum Pathol. 2018 Jan;71:91-99
pubmed: 29122656
Am J Surg Pathol. 1999 Oct;23(10):1233-40
pubmed: 10524524
J Clin Exp Hematop. 2018 Mar 16;58(1):32-35
pubmed: 29415979
Semin Diagn Pathol. 1992 Nov;9(4):279-83
pubmed: 1480849
Histopathology. 2018 Jun;72(7):1156-1163
pubmed: 29380399
Am J Surg Pathol. 2003 Jan;27(1):16-26
pubmed: 12502924
Br J Haematol. 2010 Mar;148(5):673-89
pubmed: 19961485
Acta Haematol. 2020;143(2):184-188
pubmed: 31597150
Blood. 2009 Mar 19;113(12):2629-36
pubmed: 19075188
Am J Surg Pathol. 2019 Mar;43(3):341-351
pubmed: 30540571
Clin Cancer Res. 2011 Jul 1;17(13):4232-44
pubmed: 21540239
Oncotarget. 2017 Jul 4;8(27):44960-44975
pubmed: 28402953
Am J Surg Pathol. 2017 Apr;41(4):506-516
pubmed: 28125450
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Haematologica. 2008 Aug;93(8):1195-202
pubmed: 18556402
Blood. 2015 Nov 5;126(19):2193-201
pubmed: 26239088
Am J Surg Pathol. 2005 Nov;29(11):1411-21
pubmed: 16224207
Cancer Med. 2018 Jun 1;:
pubmed: 29856127
Blood Adv. 2019 Feb 26;3(4):531-540
pubmed: 30770362
Cancer Med. 2020 Jul;9(13):4768-4776
pubmed: 32367674
Am J Surg Pathol. 1986 Jul;10(7):470-7
pubmed: 2425645
Histopathology. 2019 Aug;75(2):282-286
pubmed: 30938862
Pathol Int. 2020 Sep;70(9):695-697
pubmed: 32623805
Mod Pathol. 2020 Jan;33(Suppl 1):96-106
pubmed: 31653979
Blood Adv. 2017 Dec 11;1(26):2600-2609
pubmed: 29296913
J Clin Invest. 2017 May 1;127(5):1960-1977
pubmed: 28414296
Histopathology. 2018 May;72(6):945-954
pubmed: 29297942
Pathogens. 2018 Mar 07;7(1):
pubmed: 29518976
Am J Pathol. 2011 Apr;178(4):1922-9
pubmed: 21435468
Mod Pathol. 2021 May;34(5):922-933
pubmed: 32973328
Hum Pathol. 2008 Jul;39(7):1050-8
pubmed: 18479731
Virchows Arch. 2020 May;476(5):647-665
pubmed: 31863183
Mod Pathol. 2016 Oct;29(10):1173-82
pubmed: 27312067
Am J Surg Pathol. 2014 Dec;38(12):1715-23
pubmed: 25025450
Pathol Int. 2019 Jan;69(1):13-20
pubmed: 30601579
Br J Haematol. 2019 Jan;184(1):45-59
pubmed: 30407610
Pathology. 2020 Jan;52(1):154-165
pubmed: 31699300
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Pathol Int. 2020 Feb;70(2):116-122
pubmed: 31894883
Blood. 2011 May 5;117(18):4726-35
pubmed: 21385849
Pathology. 2020 Jan;52(1):53-67
pubmed: 31735345
Am J Clin Pathol. 2020 Apr 15;153(5):571-582
pubmed: 31977037
Am J Surg Pathol. 2017 Oct;41(10):1322-1332
pubmed: 28319526
Neuropathology. 2021 Apr;41(2):99-108
pubmed: 33269495
Am J Surg Pathol. 2009 Nov;33(11):1725-31
pubmed: 19730363
J Gastroenterol. 2020 Jan;55(1):39-50
pubmed: 31493237
Pathol Int. 2019 Mar;69(3):148-154
pubmed: 30688388
Pathol Int. 2020 Feb;70(2):108-115
pubmed: 31894892
Blood. 2018 Jul 5;132(1):17-22
pubmed: 29716887
Onco Targets Ther. 2017 Apr 28;10:2349-2363
pubmed: 28496333
PLoS One. 2018 Sep 27;13(9):e0204870
pubmed: 30261066
Blood. 2018 Oct 11;132(15):1561-1567
pubmed: 30111607
Am J Surg Pathol. 2012 Nov;36(11):1636-46
pubmed: 23073322
Eur J Haematol. 2018 May;100(5):511-517
pubmed: 29377256
Pathol Int. 2009 Dec;59(12):835-43
pubmed: 20021607
J Oncol. 2019 May 7;2019:9513701
pubmed: 31205470
Pediatr Blood Cancer. 2019 Jul;66(7):e27757
pubmed: 30977285
Pathol Int. 2020 Aug;70(8):481-492
pubmed: 32367595
Pathol Int. 2000 Sep;50(9):696-702
pubmed: 11012982
Lancet Oncol. 2020 Apr;21(4):593-602
pubmed: 32171071
Blood. 2016 Sep 8;128(10):1374-81
pubmed: 27418641
Front Oncol. 2020 May 27;10:651
pubmed: 32528871
Cancer. 1990 Mar 1;65(5):1167-72
pubmed: 2406009
Mod Pathol. 2000 Mar;13(3):223-8
pubmed: 10757332